Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The inspection was conducted at its Goa, Vema manufacturing facility
The inspection closed with zero observations and a classification of No Action Indicated
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
The product is being launched in August 2023
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
Subscribe To Our Newsletter & Stay Updated